# Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

> **NCT03164772** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ludwig Institute for Cancer Research** · enrollment: 61 (actual)

## Conditions studied

- Metastatic Non-small Cell Lung Cancer
- NSCLC

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tremelimumab
- **BIOLOGICAL:** BI 1361849
- **DEVICE:** PharmaJet Tropis® device

## Key facts

- **NCT ID:** NCT03164772
- **Lead sponsor:** Ludwig Institute for Cancer Research
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-20
- **Primary completion:** 2021-10-29
- **Final completion:** 2021-10-29
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2022-10-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03164772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03164772, "Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03164772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*